MONTREAL, Dec. 1, 2005 (PRIMEZONE) -- Viropro Inc. (OTCBB:VPRO) and the Biotechnology Research Institute of the National Research Council Canada (NRC-BRI) are pleased to announce the ratification of an agreement in principle for the development and updating of production procedures for biopharmaceutical products, other biological materials as well as projects for business development.
The aim of this agreement is to create, within different research projects, a synergy of expertise and of technology transfers ranging from the early stage of preculture to the fine-tuning of production and purification procedures. The marketing of recombinant proteins and a new vaccination platform are at the core of the business strategy behind this alliance.
"We are very happy about this collaboration with the NRC-BRI as part of our business development strategy for biopharmaceutical products. We will give precedence to co-development agreements for procedures used in the manufacturing of biopharmaceutical products with the intention of technological transfers with our business partners in the areas targeted by Viropro," said Dr. Jean-Marie Dupuy, Chief Executive Officer of Viropro.
"We are very pleased with this agreement with Viropro because of its dynamic and proactive approach and we feel confident that we will succeed in finding new technological manufacturing approaches," said Dr. Michel Desrochers, General Manager of the NRC-BRI.
About The Biotechnology Research Institute (BRI):
The Biotechnology Research Institute of the NRC (www.bri.nrc.gc.ca) is the most important R&D laboratory for biotechnology at the NRC in Canada. More than 800 people -- NRC employees, students, researchers, and guest scientists -- work in its three large research sectors: Health, Bioprocesses, and Environment, as well as in the set-up of industrial partnerships in conjunction with the Institute. The Institute maintains ties with industry and universities to the benefit of Canada.
About The National Research Council Canada (NRC):
Recognized worldwide for its innovation and research work, the National Research Council Canada (NRC) is a leader in the development of an innovative economy centered on knowledge in Canada through science and technology.
About Viropro, Inc.
Viropro, Inc. (OTCBB:VPRO) which conducts business through its operating subsidiary Viropro Pharma Inc. headquartered in Montreal, Canada is rapidly establishing a growth portfolio in the Life Sciences market through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
For more information on Viropro Pharma Inc, please visit our website at www.viropropharma.com.
Viropro, Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements." Forward looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.